GLPwatch
CagriSema drives weight loss in rats by reducing energy intake and preserving energy expenditure.
Nat Metab · 2025
Last updated 2026-05-28In a rat study, a combination drug called CagriSema led to a 12% weight loss, with a 39% reduction in food intake. Compared to rats fed the same amount of food but without the drug, CagriSema caused greater weight loss, suggesting it also helps preserve energy use in the body.
AI summary of the abstract below.
| Journal | Nat Metab, 2025 |
|---|---|
| Citations | 8 |
| Relative citation ratio | 3.01 |
| Molecules | — |
| Conditions studied | Obesity |
Abstract
CagriSema is a combination of amylin (cagrilintide) and glucagon-like peptide-1 (semaglutide) analogues being developed for weight management. Here, we show that CagriSema blunts metabolic adaptation in rats. Quantifying CagriSema's action on energy intake and expenditure in rats we observe 12% weight loss with a 39% reduction in food intake. By contrast, pair-feeding causes less-pronounced weight loss, while weight matching requires a 51% decrease in food intake. Therefore, approximately one-third of CagriSema's weight loss efficacy arises from an effect on energy expenditure, the blunting of metabolic adaptation, which contributes to the successful treatment of obesity.
Verbatim abstract via PubMed 40629149 ↗